DNPEP Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the DNPEP gene in HEK293T cells. This pool of edited cells, generated by CRISPR/Cas9-mediated gene disruption, provides a versatile loss-of-function model for investigating the biological functions of aspartyl aminopeptidase without the need for single-cell cloning. The polyclonal format preserves population heterogeneity while eliminating wild-type DNPEP expression, making it suitable for assays that require robust knockout at the population level. Researchers can employ this model to explore DNPEP-dependent processes in a widely used human embryonic kidney background, applying various molecular and biochemical techniques to dissect signaling pathways and disease mechanisms.
HEK293T cells are a derivative of the HEK293 human embryonic kidney epithelial line, stably expressing the SV40 large T antigen. This modification enhances episomal replication of plasmids containing the SV40 origin of replication and greatly boosts transfection efficiency, rendering HEK293T an industry-standard host for transient protein expression, lentivirus production, and high-throughput functional screens. Their epithelial morphology and robust growth characteristics facilitate scalable cell culture and consistent experimental reproducibility. While not a native system for renin-angiotensin pathway studies, the high transfectability of HEK293T allows reconstitution of signaling modules through ectopic expression of pathway components, enabling detailed mechanistic dissections of protein interactions and enzymatic activities.
The DNPEP gene encodes aspartyl aminopeptidase, a zinc-dependent exopeptidase that selectively removes N-terminal aspartate residues from peptide substrates. In the renin-angiotensin system, DNPEP hydrolyzes angiotensin II into angiotensin III, which then signals through AT1 and AT2 receptors to modulate vasoconstriction, sodium homeostasis, and angiogenesis. Key upstream regulators include angiotensin II, vascular endothelial growth factor A (VEGFA), and interleukin-6 (IL-6), while downstream effects involve the generation of angiotensin III and other cleaved peptide products. DNPEP functionally interacts with renin, angiotensinogen, and leucyl/cystinyl aminopeptidase (LNPEP), and its activity influences the balance between angiotensin II and angiotensin III receptor signaling. Beyond the renin-angiotensin system, DNPEP participates in general protein catabolism, peptide hormone processing, and may contribute to apoptosis regulation through cleavage of bioactive peptides.
This DNPEP knockout HEK293T polyclonal cell model is particularly valuable for dissecting the enzymatic control of angiotensin peptide levels in a cell background amenable to molecular manipulation. By abrogating DNPEP activity, researchers can examine alterations in angiotensin II-to-angiotensin III conversion and subsequent signaling events, provided pathway components are exogenously expressed or stimulated. The model also supports angiogenesis investigations, as HEK293T cells can be utilized in co-culture endothelial tube formation assays to evaluate how DNPEP-mediated peptide processing affects pro-angiogenic factors like VEGFA. Furthermore, apoptosis studies can be conducted to assess whether loss of DNPEP sensitizes cells to programmed cell death through accumulation or depletion of specific peptide substrates.
Typical applications include Western blotting and RT-qPCR for confirming DNPEP knockout and assessing compensatory gene expression, in vitro angiotensin peptide cleavage assays coupled with mass spectrometry to profile reaction products, and endothelial cell tube formation assays to measure angiogenic outcomes. Apoptosis assays (e.g., caspase activation, annexin V staining) can be employed to explore the gene’s role in cell death signaling. These polyclonal knockout cells serve as a foundational tool for hypertension, preeclampsia, and cancer research where the renin-angiotensin system and peptide metabolism are central. For further information on integrating this model into your experimental workflows, please contact Ascent Research.
